Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

Market Cap	3.08B -6.5%
Revenue (ttm)	773.05M +3.2%
Net Income	185.18M +40.0%
EPS	3.62 +39.9%
Shares Out	n/a
PE Ratio	16.42
Forward PE	20.24
Dividend	0.78 (1.31%)
Ex-Dividend Date	Jul 13, 2026

Volume	n/a
Open	59.45
Previous Close	58.25
Day's Range	59.45 - 59.45
52-Week Range	53.10 - 85.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About FRA:41L

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,470
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41L

Financial Performance

In 2025, FRA:41L's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 24, 2026

Data Sources Report a data error